CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
- 14 June 2015
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (12) , 2660-2662
Abstract
CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis. Clin Cancer Res; 21(12); 2660–2. ©2015 AACR. See related article by Nijhof et al., p. 2802Keywords
This publication has 12 references indexed in Scilit:
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibClinical Cancer Research, 2015
- Proteasome inhibitors in multiple myeloma: 10 years laterBlood, 2012
- Multiple MyelomaNew England Journal of Medicine, 2011
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008
- The molecular classification of multiple myelomaBlood, 2006
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Human CD38: a (r)evolutionary story of enzymes and receptorsLeukemia Research, 2001
- Human CD38, a cell‐surface protein with multiple functionsThe FASEB Journal, 1996
- Evaluation of CD38 as target for immunotherapy in multiple myeloma [letter; comment]Blood, 1995
- CD38: A multi-lineage cell activation molecule with a split personalityInternational Journal of Clinical and Laboratory Research, 1992